Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: A real-world observational study
Modern Rheumatology · 17.10.2026
DOI: 10.1093/mr/roag089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 17.10.2026. Verfasst von Yusuke Miyazaki und 13 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, University of Occupational and Environmental Health, Japan. Die Arbeit nennt 22 Literaturangaben. Gefördert von: University of Occupational & Environmental Health, Japan (UOEH) for Advanced Research, University of Occupational and Environmental Health, Japan, Grant-In-Aid for Scientific Research from the University of Occupational and Environmental Health.
Abstract (Originalsprache)
Objectives
This study aimed to evaluate treatment persistence and safety following subcutaneous methotrexate (MTX) initiation in Japanese patients with rheumatoid arthritis and clinical outcomes after direct switching from oral to subcutaneous MTX.
Methods
We retrospectively studied 101 patients with rheumatoid arthritis initiating subcutaneous MTX. Efficacy and safety were analysed in patients switching because of adverse events. The primary endpoint was the 26-week retention rate.
Results
Gastrointestinal intolerance was the commonest reason for switching from oral to subcutaneous MTX. Overall retention rate was 87.1% (88/101). Among switchers, the 26-week retention rate was 92.0% (81/88), and the MTX dose increased in 46.6% (41/88). In patients not receiving biologic or targeted synthetic disease-modifying anti-rheumatic drugs at switching (n = 50), the retention rate was 96.0% (48/50), and the mean MTX dose increased (10.3 ± 2.8 to 12.0 ± 2.8 mg/week; P < .0001). The Clinical Disease Activity Index improved by week 26 (13.2 ± 10.1 to 8.2 ± 7.8; P < .0001), with 30.0% (15/50) achieving remission.
Conclusions
Switching from oral to subcutaneous MTX in patients with rheumatoid arthritis who are intolerant to oral MTX may enable continued treatment and dose optimization and be associated with improved disease activity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
- Department of molecular targeted therapeutics, University of Occupational and Environmental Health, Japan.
- Department of Laboratory and Transfusion Medicine, Hospital of the University of Occupational and Environmental Health, Japan.
ORCID-Profile: Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Ryuichiro Kanda, Yuya Fujita, Shingo Nakayamada, Yoshiya Tanaka
Förderung
- University of Occupational & Environmental Health, Japan (UOEH) for Advanced Research
- University of Occupational and Environmental Health, Japan
- Grant-In-Aid for Scientific Research from the University of Occupational and Environmental Health
- University of Occupational & Environmental Health
Zitieren
APA
Miyazaki, Y., Kubo, S., Fukuyo, S., Miyagawa, I., Yamaguchi, A., Satoh-Kanda, Y., Todoroki, Y., Tanaka, H., Ueno, M., Kanda, R., Fujita, Y., Sakai, H., Nakayamada, S., & Tanaka, Y. (2026). Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: A real-world observational study. Modern Rheumatology. https://doi.org/10.1093/mr/roag089
Vancouver
Miyazaki Y, Kubo S, Fukuyo S, Miyagawa I, Yamaguchi A, Satoh-Kanda Y, et al. Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: A real-world observational study. Modern Rheumatology. 2026. doi:10.1093/mr/roag089
BibTeX
@article{Miyazaki2026,
author = {Miyazaki, Yusuke and Kubo, Satoshi and Fukuyo, Shunsuke and Miyagawa, Ippei and Yamaguchi, Ayako and Satoh-Kanda, Yurie and Todoroki, Yasuyuki and Tanaka, Hiroaki and Ueno, Masanobu and Kanda, Ryuichiro and Fujita, Yuya and Sakai, Hidenori and Nakayamada, Shingo and Tanaka, Yoshiya},
title = {Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: A real-world observational study},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag089}
}
EUVIMED